B

Brunswick Dermatology Center | Fredericton, Canada

Research site

(Unclaimed)

Location

204 Brunswick Street, Fredericton, New Brunswick, Canada

Site insights

Top conditions

Top treatments

LY3041658

Ruxolitinib

IMG-007

Eltrekibart

Upadacitinib

Daxdilimab

Dupilumab

Guselkumab

HZN-7734

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo

Drug: Eltrekibart

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting

Atopic Dermatitis

Drug: Upadacitinib

Drug: Dupilumab

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling

Atopic Dermatitis

Drug: Ruxolitinib Cream

Drug: Vehicle Cream

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Enrolling

Discoid Lupus Erythematosus

Drug: Daxdilimab

Drug: Placebo/Daxdilimab

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Enrolling

Moderate Plaque Psoriasis

Drug: Placebo

Drug: Guselkumab